Market Overview

Why Vanda's Stock Is Trading Lower Today


Vanda Pharmaceuticals (NASDAQ: VNDA) shares are trading lower on Tuesday, after Citigroup downgraded the stock from Buy to Neutral and announced a price target of $14 per share.

Vanda is a biopharmaceutical company which is engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant (VLY-686), VTR-297, and VQW-765.

Vanda shares are trading down 6.10% at $10.93 at time of publication on Tuesday. The stock has a 52-week high of $17.85 and a 52-week low of $7.12.

Related Links:

UK Clears Gilead's Remdesivir For Some Coronavirus Patients

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

Latest Ratings for VNDA

Jun 2020CitigroupDowngradesBuyNeutral
Mar 2020CitigroupUpgradesNeutralBuy
Feb 2020StifelMaintainsHold

View More Analyst Ratings for VNDA
View the Latest Analyst Ratings


Related Articles (VNDA)

View Comments and Join the Discussion!

Posted-In: why it's movingDowngrades Analyst Ratings

Latest Ratings

ZTSTruist SecuritiesMaintains160.0
WLKTruist SecuritiesMaintains60.0
UNVRTruist SecuritiesMaintains21.0
TRIPTruist SecuritiesMaintains25.0
TTDTruist SecuritiesMaintains450.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at